Eli Lilly's sofetabart mipitecan shows strong clinical efficacy in ovarian cancer trials, achieving a 100% disease control rate in combination therapy.
Eli Lilly's investigational antibody-drug conjugate (ADC), Sofetabart mipitecan (Sofe-M), has demonstrated strong clinical efficacy in treating platinum-sensitive ovarian cancer. The reported 79% confirmed objective response rate and 100% disease control rate, combined with maintained activity in patients with prior PARP inhibitor exposure, position this asset as a significant potential growth driver for Lilly's oncology pipeline.
It is an investigational antibody-drug conjugate (ADC) being developed by Eli Lilly for the treatment of ovarian cancer.
The combination of Sofe-M and bevacizumab achieved a 79% confirmed objective response rate and a 100% disease control rate.
Eli Lilly's investigational ADC, sofetabart mipitecan, achieved a 79% confirmed objective response rate in combination with bevacizumab for platinum-sensitive ovarian cancer. The data indicates consistent clinical activity regardless of FRα expression levels, bolstering the company's oncology pipeline.
The trial results demonstrate high efficacy for the investigational ADC in treating platinum-sensitive ovarian cancer, showing potential for patients who have previously undergone PARP inhibitor therapy.